NDAORALCAPSULE
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PAMELOR (nortriptyline hydrochloride) by ANI Pharmaceuticals is clinical pharmacology the mechanism of mood elevation by tricyclic antidepressants is at present unknown. Approved for depression. First approved in 1977.
Drug data last refreshed 4h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAMELOR (nortriptyline hydrochloride) is a tricyclic antidepressant approved in 1977 for the treatment of depression. It works by interfering with the transport, release, and storage of catecholamines, inhibiting the reuptake of norepinephrine and serotonin to elevate mood. The drug is administered orally in capsule form and has a combination of stimulant and depressant properties.
LOE Approaching
PAMELOR faces declining market pressures with spending at $2M as LOE approaches, signaling potential downsizing of brand teams and shift toward legacy product management or cost-containment strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY The mechanism of mood elevation by tricyclic antidepressants is at present unknown. Pamelor is not a monoamine oxidase inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor effect of…
Indications (1)
Career Relevance
Working on PAMELOR as a pharma professional offers limited growth trajectory and portends career risk as the product approaches LOE with minimal linked job openings. This role is best suited for professionals seeking stable, lower-pressure positions or those using legacy products as stepping stones to growth-stage teams.
Worked on PAMELOR at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.